Every 10-Q that The Cooper Companies, Inc. (COO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COO filings page.
COOPER COMPANIES, INC. (COO) reported essentially flat quarterly revenue but sharply higher profitability for the quarter ended July 31, 2026. Net sales were $1.07 billion versus $1.06 billion a year earlier, with CooperVision steady and CooperSurgical modestly higher. Operating income rose to $222.0 million from $175.7 million, driven by higher gross margin and lower operating expenses, particularly at CooperSurgical following prior-year write-offs.
Net income jumped to $432.8 million (diluted EPS $2.24) from $98.3 million (EPS $0.49), primarily due to a $307.2 million discrete income tax benefit from the favorable resolution of a UK tax examination and an additional $40.9 million tax benefit tied to a litigation accrual. For the nine months, net sales grew to $3.17 billion, but operating income declined to $403.8 million from $542.5 million, mainly reflecting a $272.0 million litigation expense, net of insurance recoveries, related to CooperSurgical product claims.
Operating cash flow for the first nine months strengthened to $785.4 million, supporting significant capital spending of $257.3 million, payment of litigation-related amounts, and aggressive share repurchases of 6.2 million shares for $444.7 million. Total debt was $2.54 billion, including $1.50 billion of term loans, with $950.0 million of those loans having maturity extended to February 3, 2031, and $966.7 million drawn on a $2.3 billion revolving credit facility. The board expanded the long‑standing share repurchase authorization to $3.0 billion, with about $1.5 billion remaining available. The company also disclosed a UK payroll tax matter with a potential outcome ranging from £0 to £71.7 million, plus interest, and detailed settlements covering substantially all claims associated with a December 2023 CooperSurgical product recall.
The Cooper Companies reported second-quarter fiscal 2026 results marked by solid sales growth but a litigation-driven loss. Net sales rose to $1,081.5 million from $1,002.3 million, with CooperVision up 8% and CooperSurgical up 8%, reflecting strength in contact lenses and fertility products.
However, a $271.6 million litigation expense tied to CooperSurgical’s recalled embryo culture media drove operating income to a $31.0 million loss and net loss to $77.9 million, or $(0.40) per diluted share, versus prior-year earnings of $0.44 per share. For the first six months, the company remained profitable, earning $52.9 million, supported by gross margin of 68% and operating cash flow of $443.7 million, up from $286.8 million.
Debt totaled $2,460.2 million, with $911.7 million drawn on the 2024 revolving credit facility and $1,500.0 million outstanding on the 2021 term loans. Cooper also repurchased 1.3 million shares for $105.6 million in the first half and expects existing cash, cash flow and credit capacity to cover its needs over at least the next year.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.
The Cooper Companies, Inc. reported third-quarter fiscal 2025 results showing continued activity across acquisitions, financing and operations. The company completed acquisitions including obp Surgical for $100.0 million and a fertility company for $33.5 million in 2024, and earlier acquired select Cook Medical assets for $300.0 million (present value $291.6 million). Consolidated gross margin was 65% for the quarter (66% prior-year quarter) driven lower primarily by inventory write-offs related to a product line exit.
Liquidity and capital: working capital was $1,127.7 million versus $928.7 million a year earlier. Total outstanding debt carried an aggregate amount of $2.5 billion; $930.2 million was outstanding on the 2024 Revolving Credit Facility at a weighted-average interest rate of 5.43% and $1,500.0 million remained under the 2021 Term Loan. Share repurchases in the quarter totaled 0.7 million shares for $52.2 million, with $163.6 million remaining authorized. Management disclosed a material weakness in IT general controls impacting CooperSurgical and is implementing remediation steps.